CRISPR Therapeutics AG (CRSP) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$163.1 million.
- CRISPR Therapeutics AG's Income from Continuing Operations fell 10646.97% to -$163.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$614.1 million, marking a year-over-year decrease of 5052.6%. This contributed to the annual value of -$614.1 million for FY2025, which is 5053.29% down from last year.
- Per CRISPR Therapeutics AG's latest filing, its Income from Continuing Operations stood at -$163.1 million for Q4 2025, which was down 10646.97% from -$106.4 million recorded in Q3 2025.
- Over the past 5 years, CRISPR Therapeutics AG's Income from Continuing Operations peaked at $759.2 million during Q2 2021, and registered a low of -$208.6 million during Q2 2025.
- Over the past 5 years, CRISPR Therapeutics AG's median Income from Continuing Operations value was -$114.9 million (recorded in 2021), while the average stood at -$74.1 million.
- In the last 5 years, CRISPR Therapeutics AG's Income from Continuing Operations soared by 105287.85% in 2021 and then tumbled by 23481.09% in 2024.
- CRISPR Therapeutics AG's Income from Continuing Operations (Quarter) stood at -$141.2 million in 2021, then rose by 20.1% to -$112.9 million in 2022, then skyrocketed by 151.93% to $58.6 million in 2023, then tumbled by 234.81% to -$79.0 million in 2024, then tumbled by 106.47% to -$163.1 million in 2025.
- Its last three reported values are -$163.1 million in Q4 2025, -$106.4 million for Q3 2025, and -$208.6 million during Q2 2025.